List of Excipients in Branded Drug BASIC CARE NAPROXEN SODIUM

Generic Drugs Containing BASIC CARE NAPROXEN SODIUM

Company	Ingredient	NDC	Excipient
L Perrigo Company	naproxen sodium	0113-7033	CELLULOSE, MICROCRYSTALLINE
L Perrigo Company	naproxen sodium	0113-7033	FD&C BLUE NO. 2
L Perrigo Company	naproxen sodium	0113-7033	HYPROMELLOSES

What are the Most Frequently-Used Excipients in BASIC CARE NAPROXEN SODIUM?

# Of NDCs	Excipient
6	CELLULOSE, MICROCRYSTALLINE
4	FD&C BLUE NO. 2
2	FD&C BLUE NO. 2 ALUMINUM LAKE

Basic Care Naproxen Sodium: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 28, 2026

Basic Care Naproxen Sodium is an OTC generic naproxen sodium product positioned around low-cost pain and fever relief. Its commercial value comes from efficient tablet manufacture, private-label distribution, retail availability, and brand-equivalent performance rather than proprietary active-ingredient rights. The strongest opportunities are in lower-cost formulations, easier-to-swallow dosage forms, differentiated packaging, sustained supply, and channel-specific products.

What is Basic Care Naproxen Sodium?

Basic Care Naproxen Sodium is an OTC immediate-release naproxen sodium tablet, generally marketed at 220 mg per tablet. Each 220 mg tablet contains naproxen sodium equivalent to 200 mg naproxen. The product is indicated for temporary relief of minor aches and pains associated with arthritis, muscular aches, backache, headache, toothache, menstrual cramps, common cold, and minor pain of arthritis, subject to the applicable OTC labeling.

The product is sold under the Basic Care private-label brand, which is associated with Amazon retail distribution. The underlying manufacturing and regulatory responsibilities may involve a contract manufacturer, private-label sponsor, or drug establishment identified on the applicable National Drug Code record. The exact manufacturer, tablet appearance, excipient composition, and packaging should therefore be tied to the current NDC and DailyMed label.

Attribute	Basic Care Naproxen Sodium
Active ingredient	Naproxen sodium
Common strength	220 mg per tablet
Therapeutic class	Nonsteroidal anti-inflammatory drug
Dosage form	Immediate-release oral tablet
Regulatory category	OTC human drug
Primary use	Temporary relief of minor pain and fever reduction
Commercial model	Private-label or store-brand OTC
Reference-brand comparator	Aleve naproxen sodium
Biosimilar relevance	None; this is a small-molecule drug
Primary differentiation	Price, availability, packaging, tablet usability, supply reliability

What excipients are used in Basic Care Naproxen Sodium?

The public labeling for naproxen sodium OTC tablets identifies a conventional coated-tablet excipient system. Common listed inactive ingredients include microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, colloidal silicon dioxide, hypromellose, polyethylene glycol, talc, sodium lauryl sulfate, and titanium dioxide. Some versions may include colorants or coating components that vary by manufacturer and NDC.

The excipient system has distinct functional roles:

Excipient	Primary function	Commercial or technical purpose
Microcrystalline cellulose	Diluent and compression aid	Supports tablet weight, hardness, and manufacturability
Croscarmellose sodium	Superdisintegrant	Promotes tablet breakup and active release
Povidone	Binder	Improves granule and tablet cohesion
Magnesium stearate	Lubricant	Reduces ejection force and tooling friction
Colloidal silicon dioxide	Glidant and adsorbent	Improves powder flow and may reduce sticking
Hypromellose	Film-coating polymer	Provides protection, appearance, and swallowability
Polyethylene glycol	Plasticizer in coating	Improves coating flexibility
Talc	Anti-tacking and coating aid	Reduces coating adhesion during processing
Sodium lauryl sulfate	Wetting agent	Supports wetting and dispersion
Titanium dioxide	Opacifier and pigment	Improves coating opacity and appearance

This is a standard excipient platform for a high-volume immediate-release tablet. The formulation does not require an advanced drug-delivery system. Naproxen sodium is relatively soluble compared with naproxen acid, so the development priority is usually robust disintegration, content uniformity, mechanical strength, coating performance, and stability rather than sophisticated solubility enhancement.

How does naproxen sodium affect excipient selection?

Naproxen sodium creates several formulation constraints despite its favorable salt form.

First, the active pharmaceutical ingredient is a relatively high-dose component. At 220 mg naproxen sodium per tablet, the formulation has less flexibility than a low-dose tablet for adding large quantities of specialized excipients. Diluent selection must support tablet size and acceptable swallowing characteristics.

Second, naproxen and naproxen sodium can create powder-flow, sticking, or compactibility challenges depending on particle size, crystal form, supplier, and granulation process. Microcrystalline cellulose, colloidal silicon dioxide, and a controlled lubricant level can stabilize manufacturing performance.

Third, naproxen products require careful control of dissolution and content uniformity. Excessive magnesium stearate or over-lubrication can slow wetting and dissolution. Sodium lauryl sulfate may improve wetting, but its concentration must be controlled because higher levels can affect tablet properties, taste, and gastrointestinal tolerability.

Fourth, a film coat can improve handling and swallowability. For an OTC product taken by adults and older consumers, a smooth coating can reduce friction and support adherence. Color and tablet shape also help distinguish the product from other OTC medicines, but any change requires labeling, stability, and product-quality assessment.

What formulation patents protect Basic Care Naproxen Sodium?

No publicly prominent formulation patent appears to provide durable exclusivity for the Basic Care naproxen sodium product itself. The active ingredient and basic immediate-release tablet technology are mature. The product competes in an open OTC and generic market where formulation patents associated with the original innovator product have expired or have limited practical relevance.

Potentially relevant intellectual-property categories include:

1. Specific tablet compositions.
2. Coating systems.
3. Taste-masked or chewable naproxen formulations.
4. Extended-release delivery systems.
5. Combination products.
6. Manufacturing processes involving granulation or particle engineering.
7. Packaging systems that improve stability or child resistance.

These rights would generally protect a particular formulation or process, not naproxen sodium as a molecule. A standard immediate-release private-label tablet is more likely to rely on regulatory compliance, manufacturing scale, procurement, brand access, and quality performance than on enforceable patent exclusivity.

When does naproxen sodium lose exclusivity?

Naproxen sodium has no meaningful remaining new-molecule exclusivity in the United States. The reference product Aleve has been commercially established for decades, and OTC naproxen sodium products are sold by numerous manufacturers and retailers.

The commercial barriers are therefore different from those for a recently approved prescription drug:

• There is no current new chemical entity exclusivity protecting the active ingredient.
• There is no biosimilar pathway because naproxen sodium is a small molecule.
• Generic and private-label competition is extensive.
• Product success depends on OTC regulatory compliance and supply economics.
• A manufacturer can potentially enter through an abbreviated new drug application, an OTC monograph route where applicable, or another FDA-recognized pathway depending on the product and formulation.

The relevant exclusivity question is not when the molecule loses exclusivity. It is whether a proposed product can comply with the applicable FDA monograph, labeling, quality, manufacturing, and listing requirements at a competitive cost.

What is the FDA regulatory status of Basic Care Naproxen Sodium?

Naproxen sodium is regulated as an OTC internal analgesic, antipyretic, and anti-inflammatory drug. The FDA OTC framework establishes active-ingredient conditions, permitted indications, dosage instructions, warnings, and labeling requirements for covered products. Naproxen sodium is also subject to general requirements for current good manufacturing practice, establishment registration, drug listing, adverse-event reporting, packaging, and product quality.

The principal regulatory issues include:

• Correct active-ingredient declaration.
• Naproxen sodium strength and equivalence labeling.
• Required NSAID warnings.
• Directions for adults and children 12 years and older.
• Maximum daily dosing.
• Contraindication and warning language relating to gastrointestinal bleeding, cardiovascular risk, pregnancy, and concomitant NSAID use.
• Child-resistant packaging where required.
• Stability and dissolution specifications.
• Manufacturing under FDA current good manufacturing practice requirements.

FDA’s OTC monograph system has evolved through the CARES Act and subsequent monograph orders. A product’s regulatory pathway should be evaluated against the current FDA monograph and applicable administrative order rather than relying solely on older monograph citations.

What is the Orange Book status of naproxen sodium?

Naproxen sodium tablets may appear in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, when marketed under approved abbreviated applications. The Orange Book is relevant to prescription and approved abbreviated products, but it does not create proprietary rights for a private-label OTC product.

For a specific Basic Care NDC, the practical review should distinguish:

• Whether the product is marketed under an ANDA.
• Whether the product is an OTC monograph drug.
• Whether the listed product has therapeutic-equivalence ratings.
• Whether the relevant formulation is prescription, OTC, or both.
• Whether the NDC labeler is the private-label sponsor or contract manufacturer.

Orange Book entries do not automatically identify every retail package sold under a store brand. NDC Directory and DailyMed records are often more useful for confirming the commercial label, package size, labeler, inactive ingredients, and current marketing status.

Are there Paragraph IV challenges involving Basic Care Naproxen Sodium?

Paragraph IV litigation is not a central risk for a conventional OTC naproxen sodium tablet. Paragraph IV certifications generally arise when an ANDA applicant challenges patents listed in the Orange Book for a reference-listed drug. Because the core naproxen sodium product is mature and heavily competed, the probability of a significant current patent challenge affecting Basic Care is low.

Potential litigation could still arise around:

• A patented extended-release formulation.
• A chewable or orally disintegrating formulation.
• A combination product.
• A novel coating or taste-masking system.
• An abbreviated application referencing a product with still-listed formulation patents.

For standard 220 mg immediate-release naproxen sodium, litigation exposure is more likely to involve product liability, labeling, manufacturing quality, advertising, or trademark issues than a foundational active-ingredient patent.

How strong is the patent estate for Basic Care Naproxen Sodium?

The patent estate is weak for the standard product but could be stronger for differentiated delivery systems.

Product characteristic	Patent strength	Reason
Conventional 220 mg immediate-release tablet	Low	Mature active ingredient and routine excipients
Basic film coating	Low	Widely used, difficult to protect broadly
Novel taste-masking system	Moderate	May support composition or process claims
Chewable naproxen sodium	Moderate	Potential formulation and sensory claims
Extended-release naproxen	Moderate to high	Delivery profile may support meaningful claims
Fixed-dose combination	Moderate	Combination and method-of-use claims may apply
Novel manufacturing process	Moderate	Protection depends on process specificity and detectability
Packaging-only innovation	Low to moderate	May support design or utility claims, but narrow scope

A new entrant should avoid relying on broad composition claims covering ordinary cellulose, disintegrant, binder, lubricant, and film-coating combinations. A commercially useful patent strategy would need a measurable technical advantage, such as reduced tablet size, improved dissolution after storage, reduced gastric irritation, improved taste, or a clinically relevant dosing interval.

What excipient strategies create commercial opportunities?

Lower-cost direct compression

A direct-compression formulation can reduce processing steps, solvent use, equipment requirements, and cycle time. The main development targets are powder flow, segregation control, tablet hardness, friability, and dissolution. A supplier with consistent naproxen sodium particle-size distribution may enable a simpler and lower-cost process.

The opportunity is strongest for high-volume private-label products where small per-tablet savings translate into meaningful annual margin gains.

Smaller tablets

Tablet size is a practical differentiator. A high-load formulation using optimized excipient grades, particle engineering, or roller compaction could reduce tablet volume while preserving mechanical strength. Smaller tablets may improve use among older adults and consumers with swallowing difficulties.

A size-reduction strategy must preserve:

• Assay uniformity.
• Dissolution.
• Stability.
• Coating coverage.
• Packaging integrity.
• Required warning and dosage labeling.

Chewable and flavored dosage forms

Chewable naproxen sodium could target consumers who avoid conventional tablets. The principal technical challenge is taste. Naproxen products can have a strong, unpleasant flavor, making sweetener-only approaches inadequate. Taste masking may require polymer coating, lipid barriers, ion-exchange approaches, or multiparticulate technology.

Potential commercial segments include travel, family medicine cabinets, pediatric-adjacent household use where legally appropriate, and consumers who have difficulty swallowing. The regulatory and safety profile must be carefully separated from pediatric marketing because naproxen dosing and NSAID warnings remain critical.

Orally disintegrating tablets

An orally disintegrating tablet could provide differentiation without requiring water. The formulation would need rapid disintegration, acceptable mouthfeel, low friability, and effective taste masking. Naproxen sodium’s dose makes tablet size and palatability difficult, but the product could command a premium if it solves a genuine use problem.

This route would likely require more development work than a conventional tablet and could justify composition, process, or performance-based patent claims if the formulation demonstrates a non-obvious technical result.

Buffered or gastro-focused systems

A buffered formulation may be marketed around faster wetting or onset perceptions, but claims relating to reduced gastrointestinal harm require strong clinical and regulatory support. Conventional excipient changes do not establish NSAID safety advantages. Commercial messaging should remain within permitted OTC labeling and avoid implying that an excipient system eliminates the known risks of naproxen.

Clean-label and allergen-positioned formulations

Consumers increasingly scrutinize inactive ingredients. Opportunities may include:

• Dye-free tablets.
• Lactose-free formulations.
• Gluten-free positioning where supported.
• Reduced excipient count.
• Vegetarian or vegan-suitable manufacturing.
• Avoidance of specific preservatives or controversial colorants.

These changes are commercially useful when they improve retailer acceptance or address documented consumer preferences. They have limited patent value but can support premium pricing and differentiated shelf placement.

What manufacturing and IP barriers affect market entry?

The main barriers are operational rather than patent-based.

A manufacturer must qualify a reliable naproxen sodium API supplier, establish impurity controls, validate the tablet process, demonstrate stability, and meet FDA quality-system requirements. Naproxen sodium supplier changes can affect particle size, flow, compaction, dissolution, and color. Excipient substitutions can also alter tablet performance even when the inactive ingredients remain within the same functional categories.

Important manufacturing controls include:

• API particle-size distribution.
• Blend uniformity.
• Lubrication time.
• Compression force.
• Tablet weight and hardness.
• Friability.
• Disintegration and dissolution.
• Coating weight gain.
• Residual moisture.
• Photostability and package stability.
• Extractables and leachables for certain packaging systems.

Supply-chain resilience is commercially valuable because OTC analgesics are exposed to retailer demand swings, promotional cycles, and periodic shortages. Dual sourcing of API and critical excipients can reduce interruption risk, but every material change requires appropriate comparability and quality assessment.

Which companies compete with Basic Care Naproxen Sodium?

Basic Care competes with national brands, store brands, pharmacy generics, and online private labels.

Competitor group	Examples	Competitive advantage
National brand	Aleve	Consumer recognition and broad distribution
Mass-retail private label	Equate, Up & Up, CVS Health, Walgreens brands	Shelf presence and price
Online private label	Amazon Basic Care and other e-commerce brands	Search visibility and fulfillment
Generic manufacturers	Perrigo, Dr. Reddy’s, Teva, other OTC suppliers	Manufacturing scale and regulatory infrastructure
Club-store products	Costco and warehouse-club brands	Large pack sizes and low unit cost

The market is primarily price elastic. Brand loyalty exists, but naproxen sodium is commonly purchased based on dose, count, price per tablet, retailer trust, and availability.

What generic launch scenarios exist for naproxen sodium?

A new entrant has four practical launch models.

Private-label supply

The company supplies tablets to a retailer or e-commerce brand. This model offers volume but limited consumer ownership. Margin depends on manufacturing efficiency, service levels, and retailer bargaining power.

Branded OTC product

A branded product can compete through packaging, tablet usability, clean-label positioning, or a differentiated delivery system. Marketing costs are higher, but the supplier can retain more pricing control.

Premium formulation

A chewable, orally disintegrating, smaller tablet, or modified-release product may command a higher price. The development burden and regulatory requirements are also higher.

Contract manufacturing and licensing

A company with a differentiated excipient system can license its formulation or supply technology to established OTC manufacturers. This avoids building a national consumer brand while monetizing formulation expertise.

What revenue exposure and commercial upside exist?

Naproxen sodium is a high-volume, low-price OTC category. Revenue exposure is driven by unit volume, retailer mix, pack size, promotional discounts, and manufacturing cost rather than exclusivity.

The most attractive economics generally come from:

1. High-volume retailer contracts.
2. Multi-count bottles with efficient packaging.
3. Dual sourcing and low-cost manufacturing.
4. Premium dosage forms with clear consumer utility.
5. International expansion where naproxen access and retail structures differ.
6. Hospital, clinic, and occupational-health packs.
7. Travel-size and convenience formats.

A conventional tablet has limited pricing power. A differentiated formulation can improve gross margin, but only if the technical feature is visible and meaningful to consumers. Patent protection is most commercially valuable when it supports a product attribute that retailers can merchandise and consumers can understand.

What geographic markets offer expansion opportunities?

The United States offers scale but intense competition and low unit pricing. Canada, Latin America, Europe, and selected Asia-Pacific markets may offer opportunities for OTC naproxen products, but regulatory classification, dosing, labeling, pack-size rules, and NSAID restrictions vary by jurisdiction.

Geographic expansion requires review of:

• Local OTC monographs or marketing authorization rules.
• Permitted naproxen strengths.
• Pediatric labeling.
• Pregnancy and cardiovascular warnings.
• Pharmacovigilance requirements.
• Language and packaging requirements.
• Import and API documentation.
• Local trademark availability.
• Retail and pharmacy distribution structures.

A formulation using globally available excipients is preferable for international scale. Dye-free and simplified excipient systems can reduce market-specific packaging complexity, but local regulatory review remains necessary.

Key Takeaways

• Basic Care Naproxen Sodium is a mature OTC 220 mg immediate-release tablet with little meaningful active-ingredient exclusivity.
• Its standard excipient platform is based on microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, glidants, wetting agents, and a film coat.
• The principal commercial advantages are low cost, retail access, supply reliability, and private-label scale.
• Conventional formulation patents are unlikely to create a durable moat.
• Stronger opportunities exist in smaller tablets, chewables, orally disintegrating tablets, taste masking, dye-free products, and optimized manufacturing.
• Paragraph IV and biosimilar risks are limited for the standard product.
• The major entry barriers are FDA compliance, API sourcing, dissolution control, quality systems, retailer access, and cost.
• A differentiated delivery system could support licensing, premium pricing, and narrower formulation or process patents.

FAQs

Is Basic Care Naproxen Sodium the same as Aleve?

Both products generally contain naproxen sodium at the same 220 mg OTC strength, but inactive ingredients, tablet appearance, packaging, labeling presentation, and manufacturer may differ.

Can naproxen sodium tablets be reformulated without new patents?

Yes. A manufacturer can develop an alternative excipient system, but the product must meet applicable FDA requirements, quality specifications, stability standards, and labeling obligations. The reformulation may also require regulatory assessment depending on the marketing pathway.

Are naproxen sodium excipients protected by patents?

Common excipients such as microcrystalline cellulose, croscarmellose sodium, povidone, magnesium stearate, and hypromellose are not broadly patent-protected as used in a routine immediate-release tablet. Narrow patents may cover unusual ratios, processing methods, coatings, or delivery systems.

Is a liquid naproxen sodium product commercially attractive?

A liquid product could address swallowing and dosing preferences, but it faces taste-masking, chemical stability, preservative, packaging, and dosing-accuracy challenges. Its commercial value would depend on solving those issues without creating excessive manufacturing cost.

What is the best patent strategy for a new naproxen sodium product?

The strongest strategy would target a specific technical improvement, such as reduced tablet size, improved taste masking, faster or more consistent dissolution, extended release, or a stable formulation with a measurable performance advantage. Broad claims covering ordinary OTC tablet excipients are unlikely to provide substantial protection.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Naproxen sodium tablet labeling. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Over-the-counter monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. https://www.accessdata.fda.gov/

4. U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. https://www.accessdata.fda.gov/scripts/cder/ndc/

5. U.S. Food and Drug Administration. (2020). Drug products marketed under the OTC monograph system. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monograph-reform

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. Rockville, MD: United States Pharmacopeial Convention.